Clinical trial Recruiting at 1 site Interventional Ages 18 and up

See if VExUS ultrasound can guide fluid decisions in ICU patients with venous congestion

Official title: VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit

Run by Centre Hospitalier Universitaire de Besancon · NCT07438015 · Data updated 2026-11-12

We’re testing whether a bedside ultrasound score (VExUS) helps doctors in the ICU decide how much IV fluid to give to adults with venous congestion.

More Venous Congestion trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment525 (estimated)
SponsorCentre Hospitalier Universitaire de Besancon
Academic / other
Locations1 site (Besançon)
StatusRecruiting
StartedMarch 12, 2026
Main results expectedMarch 12, 2027
Study endsMarch 12, 2027
Registry record updatedOctober 27, 2026
Trial IDNCT07438015 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults admitted to the medical ICU with venous congestion who consent and have no contraindications to ultrasound assessment.

Probably not a fit

Patients without venous congestion or those for whom fluid management decisions are not impacted by VExUS scoring may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial evaluates the use of multi-site venous ultrasound to calculate the VExUS score in adult ICU patients with venous congestion. The goal is to see if the VExUS-guided assessment can help avoid excessive fluid administration and related complications in critical illness, including ARDS. The study uses ultrasound of the inferior vena cava, portal vein, suprahepatic vein, renal vein, femoral vein, and popliteal vein to derive the VExUS score and inform fluid management. Enrollment is limited to adults admitted to the medical ICU at Besançin Teaching Hospital who consent and meet eligibility criteria. The investigation aims to correlate ultrasound findings with clinical outcomes and congestion-related risks.

Why it matters

Potential benefit: If successful, the approach could help clinicians tailor fluid therapy to reduce venous congestion and improve organ perfusion.

How similar studies have gone: Previous observations suggest VExUS may reflect congestion; this study extends evaluation to a general ICU population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients admitted to medical intensive care at Besançon Teaching Hospital for any reason.
* Aged over 18.
* Affiliated with a French social security scheme or beneficiary of such a scheme.
* No objection to participating in the study.

Non-inclusion criteria :

* Minors
* Pregnant women and breastfeeding mothers
* Persons deprived of their liberty by judicial or administrative decision; persons undergoing compulsory psychiatric treatment; persons admitted to a health or social care institution for purposes other than research
* Adults subject to legal protection measures or unable to give their consent
* Subjects who are excluded from another study or listed in the 'national volunteer registry'.

Exclusion Criteria:

\- Portal vein, suprahepatic or femoral vein thrombosis at the time of ultrasound examination.

Where it's running

  • Centre Hospitalier Universitaire Jean MINJOZ
    Besançon, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.